New drug SYS6043 tested in patients with advanced cancers

NCT ID NCT07424547

First seen Mar 09, 2026 · Last updated May 19, 2026 · Updated 9 times

Summary

This early-phase trial tests an investigational drug called SYS6043 in adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers will also look for signs that the drug may slow tumor growth. About 386 participants will receive the drug by IV every three weeks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • BRCR Global

    RECRUITING

    Plantation, Florida, 33322, United States

    Contact

    Contact Phone: •••-•••-••••

  • Florida Clinical Trials Group

    RECRUITING

    Plantation, Florida, 33322, United States

    Contact

    Contact Phone: •••-•••-••••

  • NEXT Oncology Austin

    RECRUITING

    Austin, Texas, 78758, United States

    Contact

    Contact Phone: •••-•••-••••

  • NEXT Oncology San Antonio

    RECRUITING

    San Antonio, Texas, 78229, United States

    Contact

    Contact Phone: •••-•••-••••

  • NEXT Oncology Virginia

    RECRUITING

    Fairfax, Virginia, 22031, United States

    Contact

    Contact Phone: •••-•••-••••

Conditions

Explore the condition pages connected to this study.